Orthofix Medical Inc. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Massimo Calafiore; PEO compensation actually paid $3.28M; Other NEO average total compensation $2.17M.
- 2024-12-31: PEO Massimo Calafiore; Other NEO average total compensation $2.69M.
- 2023-12-31: PEO Catherine Burzik; Other NEO average total compensation $2.28M.
- 2022-12-31: PEO Jon C. Serbousek; PEO total compensation $6.32M; PEO compensation actually paid $5.00M; Other NEO average total compensation $2.13M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Massimo Calafiore | $3.28M | $2.17M | $1.24M | $35.27 | $103.59 | -$92.19M | ompanywide net sales $822.31M | 2026-04-29 | |
| 2024-12-31 | Massimo Calafiore | $2.69M | $3.05M | $37.81 | $150.42 | -$126.00M | $799.49M | 2026-04-29 | ||
| 2023-12-31 | Catherine Burzik | $2.28M | $521.03K | $29.19 | $130.16 | -$151.40M | $746.64M | 2026-04-29 | ||
| 2022-12-31 | Jon C. Serbousek | $6.32M | $5.00M | $2.13M | $1.36M | $44.46 | $120.91 | -$19.75M | $460.71M | 2026-04-29 |
| 2021-12-31 | Jon C. Serbousek | $5.34M | $723.45K | $1.79M | $673.74K | $67.32 | $169.55 | -$38.38M | $464.48M | 2026-04-29 |
| 2024-12-31 | Massimo Calafiore | $2.69M | $3.05M | $37.81 | $150.42 | -$126.00M | Company-wide net sales $799.49M | 2025-04-30 | ||
| 2023-12-31 | Catherine Burzik | $2.28M | $521.03K | $29.19 | $130.16 | -$151.40M | $746.64M | 2025-04-30 | ||
| 2022-12-31 | Jon C. Serbousek | $6.32M | $5.00M | $2.13M | $1.36M | $44.46 | $120.91 | -$19.75M | $460.71M | 2025-04-30 |
| 2021-12-31 | Jon C. Serbousek | $5.34M | $723.45K | $1.79M | $673.74K | $67.32 | $169.55 | -$38.38M | $464.48M | 2025-04-30 |
| 2020-12-31 | Jon C. Serbousek | $5.34M | $6.76M | $1.50M | $1.45M | $93.07 | $145.89 | $2.52M | $406.56M | 2025-04-30 |
| 2023-12-31 | Catherine Burzik | $2.28M | $521.03K | $29.19 | $130.16 | -$151.40M | Company-wide net sales $746.64M | 2024-04-29 | ||
| 2022-12-31 | Jon C. Serbousek | $6.32M | $5.00M | $2.13M | $1.36M | $44.46 | $120.91 | -$19.75M | $460.71M | 2024-04-29 |
| 2021-12-31 | Jon C. Serbousek | $5.34M | $723.45K | $1.79M | $673.74K | $67.32 | $169.55 | -$38.38M | $464.48M | 2024-04-29 |
| 2020-12-31 | Jon C. Serbousek | $5.34M | $6.76M | $1.50M | $1.45M | $93.07 | $145.89 | $2.52M | $406.56M | 2024-04-29 |
| 2022-12-31 | Jon C. Serbousek | $6.32M | $5.00M | $2.13M | $1.36M | $44.46 | $120.91 | -$19.75M | Company-wide net sales $460.71M | 2023-04-27 |
| 2021-12-31 | Jon C. Serbousek | $5.34M | $723.45K | $1.79M | $673.74K | $67.32 | $169.55 | -$38.38M | $464.48M | 2023-04-27 |
| 2020-12-31 | Jon C. Serbousek | $5.34M | $6.76M | $1.50M | $1.45M | $93.07 | $145.89 | $2.52M | $406.56M | 2023-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |